Investor Forum: Benchmark Holdings, Venture Life and Vp plc – 28th September 2016

We will be hosting our next Investor Forum at Tavistock Communications, on the evening of Wednesday 28th of September and are delighted to invite you to attend and meet the management of Benchmark Holdings, Venture Life and Vp plc. Benchmark Holdings plc (BMK) Benchmark is a pioneering company operating in the aquaculture, …

Published: 21st September 2016


Ergomed Webinar – Tuesday 27th at 11.15am

Having listed just over two years ago, ERGO will be presenting details on how their service business to the pharmaceutical industry supports a growing and exciting portfolio of R&D opportunities. Click here to register After registering, you will receive a confirmation email containing information about joining the webinar.

Published: 16th September 2016


Elizabeth Klein joins the Equity Development team

Elizabeth Klein has now joined our team of equity research analysts. Elizabeth, a highly rated Biosciences investment analyst, previously worked N+1 Singer where she focused on the Healthcare and IP Commercialisation sectors. Before that she was at Teathers, Bridgewell, R.W. Baird and Dresdner Kleinwort Benson.  Andy Edmond, CEO, says "having had …

Published: 14th September 2016


Webinars in September

We would like to give you an overview of all the events going on this September and invite you to join us in engaging with a host of interesting companies. In chronological order we have: Deltex Webinar - Thursday 15th at 1pm. With probe sales in the US achieving a 50% growth rate, …

Published: 13th September 2016


Mark Hughes joins the Equity Development team

Mark Hughes has now joined our team of equity research analysts. Mark, a highly rated small and midcap analyst, previously worked for several years at Panmure Gordon, where he was managing director and co-head of research. Prior to this, he was Head of the Liverpool office for Numis Securities, and …

Published: 1st August 2016


Accrol Group IPO and initiation of research

Equity Development initiated coverage on Accrol Group on 10 June, the company’s first day of Dealings on AIM, following their very successful IPO, which raised gross proceeds of £43.3 million at 100p per share. Accrol is a leading independent tissue converter, manufacturing toilet rolls, kitchen rolls, facial tissues and AFH …

Published: 10th June 2016